Cargando…

Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis

PURPOSE: The aim of this retrospective multicentric study was to compare the tumour response rates of Balloon-occluded Transarterial Chemoembolisation (B-TACE) to non-B-TACE using propensity score matching (PSM) in patients with hepatocellular carcinoma and to investigate the clinical benefit, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Golfieri, Rita, Bezzi, Mario, Verset, Gontran, Fucilli, Fabio, Mosconi, Cristina, Cappelli, Alberta, Paccapelo, Alexandro, Lucatelli, Pierleone, Magand, Nicolas, Rode, Agnes, De Baere, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189964/
https://www.ncbi.nlm.nih.gov/pubmed/33709273
http://dx.doi.org/10.1007/s00270-021-02805-5
_version_ 1783705593078349824
author Golfieri, Rita
Bezzi, Mario
Verset, Gontran
Fucilli, Fabio
Mosconi, Cristina
Cappelli, Alberta
Paccapelo, Alexandro
Lucatelli, Pierleone
Magand, Nicolas
Rode, Agnes
De Baere, Thierry
author_facet Golfieri, Rita
Bezzi, Mario
Verset, Gontran
Fucilli, Fabio
Mosconi, Cristina
Cappelli, Alberta
Paccapelo, Alexandro
Lucatelli, Pierleone
Magand, Nicolas
Rode, Agnes
De Baere, Thierry
author_sort Golfieri, Rita
collection PubMed
description PURPOSE: The aim of this retrospective multicentric study was to compare the tumour response rates of Balloon-occluded Transarterial Chemoembolisation (B-TACE) to non-B-TACE using propensity score matching (PSM) in patients with hepatocellular carcinoma and to investigate the clinical benefit, such as lower rates of TACE re-intervention achieved using B-TACE. MATERIAL AND METHODS: The B-TACE procedures (n = 96 patients) were compared with a control group of non-B-TACE treatments (n = 434 pts), performed with conventional (cTACE) or drug-eluting microspheres TACE (DEM-TACE). Data were collected from six European centres from 2015 to 2019. Objective responses (OR) and complete response (CR) rates after the first session and the number of TACE re-interventions were evaluated using PSM (91 patients per arm). RESULTS: The best target OR after PSM were similar for both B-TACE and non-B-TACE (90.1% and 86.8%, p = 0.644); however, CR at 1–6 months was significantly higher for B-TACE (59.3% vs. 41.8%, p = 0.026). Patients treated with B-TACE had a significantly lower retreatment rate during the first 6 months (9.9%% vs. 22.0%, p = 0.041). Post-embolisation syndrome (PES) rates were 8.8% in non-B-TACE and 41.8% in B-TACE (p < 0.001), with no significant differences between groups regarding major adverse events. CONCLUSION: B-TACE is safe and effective, achieving higher CR rates than non-B-TACE. Patients undergoing B-TACE had a significantly lower retreatment rate within the first 6 months but higher PES rates. LEVEL OF EVIDENCE III: Level 3, retrospective study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00270-021-02805-5.
format Online
Article
Text
id pubmed-8189964
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81899642021-06-28 Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis Golfieri, Rita Bezzi, Mario Verset, Gontran Fucilli, Fabio Mosconi, Cristina Cappelli, Alberta Paccapelo, Alexandro Lucatelli, Pierleone Magand, Nicolas Rode, Agnes De Baere, Thierry Cardiovasc Intervent Radiol Clinical Investigation PURPOSE: The aim of this retrospective multicentric study was to compare the tumour response rates of Balloon-occluded Transarterial Chemoembolisation (B-TACE) to non-B-TACE using propensity score matching (PSM) in patients with hepatocellular carcinoma and to investigate the clinical benefit, such as lower rates of TACE re-intervention achieved using B-TACE. MATERIAL AND METHODS: The B-TACE procedures (n = 96 patients) were compared with a control group of non-B-TACE treatments (n = 434 pts), performed with conventional (cTACE) or drug-eluting microspheres TACE (DEM-TACE). Data were collected from six European centres from 2015 to 2019. Objective responses (OR) and complete response (CR) rates after the first session and the number of TACE re-interventions were evaluated using PSM (91 patients per arm). RESULTS: The best target OR after PSM were similar for both B-TACE and non-B-TACE (90.1% and 86.8%, p = 0.644); however, CR at 1–6 months was significantly higher for B-TACE (59.3% vs. 41.8%, p = 0.026). Patients treated with B-TACE had a significantly lower retreatment rate during the first 6 months (9.9%% vs. 22.0%, p = 0.041). Post-embolisation syndrome (PES) rates were 8.8% in non-B-TACE and 41.8% in B-TACE (p < 0.001), with no significant differences between groups regarding major adverse events. CONCLUSION: B-TACE is safe and effective, achieving higher CR rates than non-B-TACE. Patients undergoing B-TACE had a significantly lower retreatment rate within the first 6 months but higher PES rates. LEVEL OF EVIDENCE III: Level 3, retrospective study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00270-021-02805-5. Springer US 2021-03-11 2021 /pmc/articles/PMC8189964/ /pubmed/33709273 http://dx.doi.org/10.1007/s00270-021-02805-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Investigation
Golfieri, Rita
Bezzi, Mario
Verset, Gontran
Fucilli, Fabio
Mosconi, Cristina
Cappelli, Alberta
Paccapelo, Alexandro
Lucatelli, Pierleone
Magand, Nicolas
Rode, Agnes
De Baere, Thierry
Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis
title Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis
title_full Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis
title_fullStr Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis
title_full_unstemmed Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis
title_short Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis
title_sort retrospective european multicentric evaluation of selective transarterial chemoembolisation with and without balloon-occlusion in patients with hepatocellular carcinoma: a propensity score matched analysis
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189964/
https://www.ncbi.nlm.nih.gov/pubmed/33709273
http://dx.doi.org/10.1007/s00270-021-02805-5
work_keys_str_mv AT golfieririta retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT bezzimario retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT versetgontran retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT fucillifabio retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT mosconicristina retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT cappellialberta retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT paccapeloalexandro retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT lucatellipierleone retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT magandnicolas retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT rodeagnes retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis
AT debaerethierry retrospectiveeuropeanmulticentricevaluationofselectivetransarterialchemoembolisationwithandwithoutballoonocclusioninpatientswithhepatocellularcarcinomaapropensityscorematchedanalysis